141 related articles for article (PubMed ID: 9931878)
1. [Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen].
Wenger FA; Zieren HU; Jacobi CA; Müller JM
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1348-50. PubMed ID: 9931878
[TBL] [Abstract][Full Text] [Related]
2. [Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen].
Wenger FA; Jacobi CA; Siderow A; Zieren J; Zieren HU; Müller JM
Chirurg; 1999 Jun; 70(6):694-9. PubMed ID: 10427457
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
Pritchard KI; Shepherd LE; Chapman JA; Norris BD; Cantin J; Goss PE; Dent SF; Walde D; Vandenberg TA; Findlay B; O'Reilly SE; Wilson CF; Han L; Piura E; Whelan TJ; Pollak MN
J Clin Oncol; 2011 Oct; 29(29):3869-76. PubMed ID: 21911723
[TBL] [Abstract][Full Text] [Related]
4. The beneficial effect of tamoxifen therapy in patients with resected adenocarcinoma of the pancreas.
Horimi T; Takasaki M; Toki A; Nishimura W; Morita S
Hepatogastroenterology; 1996; 43(11):1225-9. PubMed ID: 8908555
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial.
Pan DY; Qiao JG; Chen JW; Huo YC; Zhou YK; Shi HA
Hepatobiliary Pancreat Dis Int; 2003 May; 2(2):211-5. PubMed ID: 14599971
[TBL] [Abstract][Full Text] [Related]
6. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma.
Bajetta E; Procopio G; Ferrari L; Martinetti A; Zilembo N; Catena L; Alú M; Della TS; Alberti D; Buzzoni R
Cancer; 2002 Jan; 94(2):299-304. PubMed ID: 11900215
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial.
Morak MJ; van der Gaast A; Incrocci L; van Dekken H; Hermans JJ; Jeekel J; Hop WC; Kazemier G; van Eijck CH
Ann Surg; 2008 Dec; 248(6):1031-41. PubMed ID: 19092348
[TBL] [Abstract][Full Text] [Related]
8. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
[TBL] [Abstract][Full Text] [Related]
9. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma.
Takada T; Amano H; Yasuda H; Nimura Y; Matsushiro T; Kato H; Nagakawa T; Nakayama T;
Cancer; 2002 Oct; 95(8):1685-95. PubMed ID: 12365016
[TBL] [Abstract][Full Text] [Related]
10. [A randomized, double-blind, placebo-controlled, phase 3 trial comparing SMS 201-995 pa LAR plus tamoxifen versus tamoxifen plus placebo in women with locally recurrent or metastatic breast cancer].
Sommer H; Pröhl-Steimer B; Bajetta E; Haus U; Janni W; Kay A
Zentralbl Gynakol; 2001 Oct; 123(10):557-61. PubMed ID: 11753809
[TBL] [Abstract][Full Text] [Related]
11. [Octreotide in the treatment of advanced pancreatic tumor. Preliminary study].
Cirillo F; Bottini A; Brunelli A; Zuffada S; Bassi M; Filippini L; Alquati P
Minerva Chir; 1998 Dec; 53(12):979-85. PubMed ID: 10210927
[TBL] [Abstract][Full Text] [Related]
12. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
13. Does intraoperative radiation therapy improve local tumor control in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma? A propensity score analysis.
Showalter TN; Rao AS; Rani Anne P; Rosato FE; Rosato EL; Andrel J; Hyslop T; Xu X; Berger AC
Ann Surg Oncol; 2009 Aug; 16(8):2116-22. PubMed ID: 19437078
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of unresectable locally advanced pancreatic cancer with combined radiotherapy and chemotherapy].
Jensen HA; Nielsen HO; Jensen JD; Fristrup CW; Nielsen M; Pfeiffer P
Ugeskr Laeger; 2008 Feb; 170(8):639-41. PubMed ID: 18364156
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma.
Keene KS; Rich TA; Penberthy DR; Shepard RC; Adams R; Jones RS
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):97-103. PubMed ID: 15850908
[TBL] [Abstract][Full Text] [Related]
16. Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study.
Burch PA; Block M; Schroeder G; Kugler JW; Sargent DJ; Braich TA; Mailliard JA; Michalak JC; Hatfield AK; Wright K; Kuross SA
Clin Cancer Res; 2000 Sep; 6(9):3486-92. PubMed ID: 10999733
[TBL] [Abstract][Full Text] [Related]
17. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of cyclophosphamide, leucovorin, 5-fluorouracil 24-hour infusion and tamoxifen in pancreatic cancer.
Eckel F; Lersch C; Lippl F; Assmann G; Schulte-Frohlinde E
J Exp Clin Cancer Res; 2000 Sep; 19(3):295-300. PubMed ID: 11144522
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study.
Verset G; Verslype C; Reynaert H; Borbath I; Langlet P; Vandebroek A; Peeters M; Houbiers G; Francque S; Arvanitakis M; Van Laethem JL
Br J Cancer; 2007 Sep; 97(5):582-8. PubMed ID: 17687341
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
